STREAM is an open platform for the registration of R/R AML patients, developed under the European Rare Blood Disorders Platform (ENROL), which is conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet).
STREAM is the innovative master framework designed to transform the treatment landscape for relapsed or refractory acute myeloid leukaemia (R/R AML). By integrating patients across Europe, it ensures an inclusive, real-world registry that collects clinical, genetic, and treatment data. STREAM’s dynamic design accommodates neglected populations, enabling comprehensive monitoring of outcomes while setting the foundation for ground-breaking clinical research.
STREAM gathers high-quality, pseudonymised patient data, enabling cross-country collaboration and adherence to the FAIR principles (Findable, Accessible, Interoperable, and Reusable). Through this platform, the European haematological community gains unparalleled insight into disease progression, response to treatments, and survival trends, ensuring better-informed decisions in routine and personalised care.
STREAM bridges the gap between clinical practice and innovative research. By integrating data on rare mutations, patient demographics, and treatment history, it paves the way for personalised therapeutic approaches. This framework not only supports the Pragmatic Clinical Trial (RPCT) but also fosters the development of exploratory and company-driven clinical trials in R/R AML.
As a part of the European Rare Blood Disorders Platform (ENROL), STREAM promotes harmonisation of biobanking and measurable residual disease (MRD) standardisation. It facilitates collaboration across healthcare providers and research institutions, creating a robust ecosystem that prioritises patient-centric innovation and inclusivity.
